These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34648064)

  • 81. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
    Kanagala P; Arnold JR; Singh A; Chan DCS; Cheng ASH; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    PLoS One; 2020; 15(4):e0232280. PubMed ID: 32349122
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
    Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation.
    Hachiya R; Mochizuki Y; Shibakai M; Omomo Y; Kuroki Y; Endo Y; Ichikawa S; Miyazaki H; Chino S; Toyosaki E; Ota M; Fukuoka H; Shinke T
    Heart Vessels; 2022 May; 37(5):755-764. PubMed ID: 34677658
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Factors associated with readmission after long-term administration of tolvaptan in patients with congestive heart failure.
    Yamashita S; Takenaka M; Ohbayashi M; Kohyama N; Kurihara T; Sunaga T; Ishiguro H; Kogo M
    Singapore Med J; 2023 Feb; ():. PubMed ID: 36751847
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Renin-angiotensin system inhibitor exerts prognostic effects in HFpEF patients with low baseline chloride level.
    Shirotani S; Jujo K; Takada T; Abe T; Kishihara M; Watanabe S; Endo N; Fujita H; Murasaki S; Yamaguchi J
    Int J Cardiol; 2023 Feb; 373():83-89. PubMed ID: 36455698
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Analysis of Risk Factors for Heart Failure with Preserved Ejection Fraction and Observations on Blood Lipid Metabolism.
    Li Y; Li J
    Altern Ther Health Med; 2023 Nov; 29(8):396-400. PubMed ID: 37632969
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cost-Effectiveness of long-term tolvaptan administration for chronic heart failure treatment in Japan.
    Nakao Y; Kawakami H; Saito M; Inoue K; Ikeda S; Yamaguchi O
    J Cardiol; 2022 Mar; 79(3):408-416. PubMed ID: 34799217
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Murakami Y; Sano T; Ikeda T
    BMC Cardiovasc Disord; 2022 Apr; 22(1):202. PubMed ID: 35488212
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Significantly Elevated Alkaline Phosphatase Caused by Congestive Hepatopathy in the Setting of Heart Failure with Preserved Ejection Fraction.
    Wu JF; Jha P; Doucette S; Abid H
    WMJ; 2022 Apr; 121(1):E14-E17. PubMed ID: 35442588
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The Relationship between the Presence of Cardiohepatic Syndrome and Mortality in Heart Failure with Reduced Ejection Fraction.
    Sungur MA; Sungur A; Zencirci AE
    Turk Kardiyol Dern Ars; 2023 Oct; ():. PubMed ID: 37905537
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Efficacy of tolvaptan on the short and mid-term prognosis in elderly patients with acute heart failure coexisting with oliguria: A retrospective cohort study.
    Liu Y; Zhang Y; Chen H; Zhao J; Ma Q; Yang G; Wang X; Wu Z; Hou J; Cheng Q; Ao Q
    Front Cardiovasc Med; 2022; 9():1075631. PubMed ID: 36698930
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Comparison of the Effects of Carperitide and Tolvaptan on Patients with Left Ventricular Dysfunction: A Two-Center Retrospective Study.
    Koeda C; Yamaya S; Hozawa M; Sato M; Nasu K; Takahashi T; Terui K
    Cardiol Res Pract; 2017; 2017():6935342. PubMed ID: 28785506
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan.
    Kobayashi M; Hayashi M; Yamada R; Ishiguro T; Fujiwara W; Ishii H; Naruse H; Watanabe E; Ozaki Y; Izawa H
    Fujita Med J; 2023 May; 9(2):80-83. PubMed ID: 37234387
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The role of tolvaptan in pulmonary hypertension: A retrospective study.
    Chen Q; Luo H; Li Y
    Medicine (Baltimore); 2022 Nov; 101(47):e31587. PubMed ID: 36451399
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Focus on HFpEF in heart failure.
    He C; Huang R
    Chin Med J (Engl); 2022 May; 135(9):1041-1042. PubMed ID: 35067561
    [No Abstract]   [Full Text] [Related]  

  • 96. Relationship of maximum walking speed with peak oxygen uptake and anaerobic threshold in male patients with heart failure.
    Koen M; Kubota Y; Tokita M; Kato K; Takahashi H; Akutsu K; Asai K; Takano H
    Heart Vessels; 2023 Nov; 38(11):1344-1355. PubMed ID: 37493799
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Pharmacological and Non-Pharmacological Advancements in Heart Failure Treatment.
    Wang C; Fu G; Wang X; Li N
    Rev Cardiovasc Med; 2024 Jun; 25(6):230. PubMed ID: 39076329
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment landscape.
    Desai N; Olewinska E; Famulska A; Remuzat C; Francois C; Folkerts K
    Heart Fail Rev; 2024 May; 29(3):631-662. PubMed ID: 38411769
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Clinical features and long-term prognosis of patients with congestive heart failure taking tolvaptan: a comparison of patients with preserved and reduced left ventricular ejection fraction.
    Seki T; Kubota Y; Matsuda J; Tokita Y; Iwasaki YK; Shimizu W
    Heart Vessels; 2022 Apr; 37(4):574-582. PubMed ID: 34648064
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Clin Exp Hypertens; 2020; 42(2):110-117. PubMed ID: 30793983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.